pilocarpine has been researched along with Idiopathic Parkinson Disease in 8 studies
Pilocarpine: A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.
(+)-pilocarpine : The (+)-enantiomer of pilocarpine.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The effects of adenosine A(2A) receptor antagonists were here assessed in a rat model of parkinsonian tremor induced by cholinomimetic drugs by evaluating the counteraction of tremulous jaw movements." | 3.73 | Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson's disease. ( Baraldi, PG; Fenu, S; Morelli, M; Simola, N; Tabrizi, MA, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ju, UH | 1 |
| Liu, FC | 1 |
| Lin, CS | 1 |
| Huang, WY | 1 |
| Lin, TY | 1 |
| Shen, CH | 1 |
| Chou, YC | 1 |
| Lin, CL | 1 |
| Lin, KT | 1 |
| Kao, CH | 1 |
| Chen, CH | 1 |
| Yang, TY | 1 |
| Yamashita, F | 2 |
| Hirayama, M | 2 |
| Nakamura, T | 2 |
| Takamori, M | 2 |
| Hori, N | 2 |
| Uchida, K | 1 |
| Hama, T | 1 |
| Sobue, G | 2 |
| Salamone, JD | 2 |
| Collins-Praino, LE | 1 |
| Pardo, M | 1 |
| Podurgiel, SJ | 1 |
| Baqi, Y | 1 |
| Müller, CE | 1 |
| Schwarzschild, MA | 1 |
| Correa, M | 2 |
| Ishiwari, K | 1 |
| Mingote, S | 1 |
| Trevitt, JT | 1 |
| Carlson, BB | 1 |
| Simola, N | 1 |
| Fenu, S | 1 |
| Baraldi, PG | 1 |
| Tabrizi, MA | 1 |
| Morelli, M | 1 |
| Watanabe, H | 1 |
| Ito, H | 1 |
| Mabuchi, N | 1 |
| Kent, S | 1 |
| Hughes, BO | 1 |
| Spicer, B | 1 |
8 other studies available for pilocarpine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Risk of Parkinson disease in Sjögren syndrome administered ineffective immunosuppressant therapies: A nationwide population-based study.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Comorbidity; Female; Humans; Hydroxychl | 2019 |
Pupillary autonomic dysfunction in multiple system atrophy and Parkinson's disease: an assessment by eye-drop tests.
Topics: 3-Iodobenzylguanidine; Aged; Autonomic Nervous System; Autonomic Nervous System Diseases; Blood Pres | 2010 |
Conditional neural knockout of the adenosine A(2A) receptor and pharmacological A(2A) antagonism reduce pilocarpine-induced tremulous jaw movements: studies with a mouse model of parkinsonian tremor.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Disease Models, Animal; Jaw; Male; | 2013 |
The GABA uptake inhibitor beta-alanine reduces pilocarpine-induced tremor and increases extracellular GABA in substantia nigra pars reticulata as measured by microdialysis.
Topics: Animals; beta-Alanine; Chromatography, High Pressure Liquid; Disease Models, Animal; Dose-Response R | 2004 |
Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson's disease.
Topics: Analysis of Variance; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Rela | 2006 |
Pupillary supersensitivity and visual disturbance in Parkinson's disease.
Topics: Age Factors; Epinephrine; Female; Humans; Light; Male; Middle Aged; Miotics; Mydriatics; Parkinson D | 2008 |
Continuous drug delivery methods reflect progress in therapy for chronic diseases.
Topics: Aged; Chronic Disease; Cytarabine; Dosage Forms; Drug Implants; Glaucoma; Humans; Injections, Intrav | 1977 |
Some anticholinergic activities of BRL 1288--a new anti-Parkinson drug.
Topics: Animals; Disease Models, Animal; Glycolates; Guinea Pigs; Ileum; In Vitro Techniques; Mice; Muscle, | 1969 |